Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 74

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 74
---
 in the future, and, as a result, any return on investment may be limited to the value of our shares.

We have never paid cash dividends
and do not anticipate paying cash dividends on our share capital in the foreseeable future. As a result, investors seeking cash dividends
should not purchase our Ordinary Shares. The payment of dividends will depend on our earnings, capital requirements, financial condition,
prospects for future earnings and other factors our board of directors may deem relevant. In addition, our term loan agreement limits
our ability to, among other things, pay dividends or make other distributions or payments on account of our Ordinary Shares, in each
case subject to certain exceptions. If we do not pay dividends, our Ordinary Shares may be less valuable because a return on your investment
will only occur if our share price appreciates and you then sell our Ordinary Shares. In addition, our loan agreements limit our ability
to pay dividends or make other distributions or payments on account of our Ordinary Shares, in each case subject to certain exceptions.
The Companies Law imposes further restrictions on our ability to declare and pay dividends.

<div align='center'>48</div>

If we do raise additional capital, shareholders may be subject to dilution.

If we issue additional shares
of our Ordinary Shares or other equity securities convertible into share capital to fund operations, develop new products, accelerate
other strategies, make acquisitions or support other activities, the ownership interests of investors in this offering will be diluted.
Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond
our control, we cannot predict or estimate the amount, timing or nature of any future offerings. To the extent that we raise additional
capital through the sale of equity securities, your ownership interest will be diluted, and the terms may include liquidation or other
preferences that adversely affect your rights as a shareholder. The incurrence of indebtedness would result in increased fixed payment
obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our
ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term
but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances
and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates,